Drugs / DTaP-IPV vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02274285 Comparator | Oct 2014 → May 2016 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02274285 ↗ |
| Modality | Vaccine | “DTaP-IPV vaccine and Hib vaccine” NCT02274285 ↗ |
| Route | Subcutaneous | “Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously” NCT02274285 ↗ |